THRN Thorne Research: Multiplikator forward rega marang pendapatan

Thorne HealthTech (THRN) forward P/S dynamics reflect current market expectations, where the value of 1.30 characterizes this level. High barriers to entry are established by biotest patents and strict FDA oversight. Process optimization is based on contract manufacturing and external IT services. Growing demand for longevity and premium supplements facilitates the scaling of sales under private status.

thorne.com - Rega forward marang dodolan THRN (periode 04.07.2022 - 21.10.2023)

Rincian metrik lan analitis perusahaan Thorne Research (THRN)

- rega saiki lan proyeksi nilai saham:

Rega saham Thorne HealthTech, Inc.|THRN - Rata-rata rega prakiraan

- data kapitalisasi saham perusahaan:

Biji pasar Thorne Research|THRN - Nilai Dipunlarasaken Utang lan Kas

- rincian valuasi buku bisnis:

Nilai Buku saben Saham Thorne HealthTech|THRN - Nilai Akuntansi Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku thorne.com|THRN - Aset Perusahaan

- informasi babagan utang lan solvabilitas:

- rincian asil keuangan lan kelipatan valuasi:

THRN - Bathi sawise mbayar pajeg|Proyeksi bathi mangsa ngarep Thorne HealthTech|THRN - Kapitalisasi marang bathi|Pangali Forward P/E Thorne|THRN - Pangali rega marang bathi tumrap wutah|Pangali EV/EBITDA Thorne Research|THRN - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan Thorne HealthTech|THRN - Bathi saben saham sajrone patang kuartal pungkasan|Wutah bathi EPS kuartalan thorne.com|THRN - Tambahing bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Thorne HealthTech

- statistik dodolan lan pendapatan perusahaan:

THRN - Pendapatan dodolan perusahaan|Prakiraan pendapatan perusahaan Thorne HealthTech, Inc.|THRN - Rasio kapitalisasi marang pendapatan|Multiplikator forward rega marang pendapatan Thorne Research

Ringkesan analitik perusahaan:Thorne HealthTech, Inc. (THRN)

To find fundamental support in Thorne HealthTech (THRN), it is essential to align the business's market value with expected revenues from personalized medicine and diagnostics. By analyzing the forward P/S valuation, an investor determines a fair capitalization range relative to future revenue, which allows for the distinction between genuine growth in wellness segment network effects and a dangerous overvaluation of the asset.

Perusahaan pesaing

Multiplikator Forward P/S HIMS (Hims & Hers)|Hinge Health, Inc. (HNGE) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|TDOC: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan TALK (Talkspace Platform)|LFMD: Multiplikator Forward P/S|amwell.com - Rega forward marang dodolan|MGRX (Mangoceuticals Inc.) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep DarioHealth Corp DRIO|Multiplikator Forward P/S VSEE|Multiplikator Forward P/S Mobile-health Corp (MNDR)|Rasio rega marang prakiraan pendapatan Accolade, Inc. ACCD|biotricity.com - Rasio rega marang prakiraan pendapatan|LYT: Multiplikator forward rega marang pendapatan|Ontrak Inc - Rasio rega marang pendapatan sing dikarepake|SHLT: Multiplikator Forward P/S